Search results
Bird Flu Keeps Spreading in U.S. Cows. 5 Big Questions, Answered.
Barrons.com· 2 days agoStill, the federal government is ramping up the cadence of its response, and is preparing stockpiled...
Misleading Claims on Well-Known Rare Risk of AstraZeneca COVID-19 Vaccine - FactCheck.org
FactCheck.org· 7 days agoA rare risk of dangerous blood clots associated with the AstraZeneca COVID-19 vaccine was identified and reported in early 2021. This month, the company announced it was pulling the vaccine ...
Feds plan for smoother access to RSV infant shot
Politico· 16 hours agoHe said the CDC is working with CMS to ensure that providers receive reimbursement when they administer shots, and the agencies are making efforts to get private insurance ...
Vaccine makers receive stock boost after third human bird flu case in US
Newsweek· 7 days agoShares in some companies that produce vaccines have seen stock boosts following a small number of...
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
Morningstar· 2 days agoData From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS® (sotorasib) Plus Vectibix® ( ...
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO...
Benzinga via Yahoo Finance· 3 days agoCoya Therapeutics Inc (NASDAQ:COYA) is a clinical-stage biotechnology company developing treatments...
The Trump policy Biden won’t kill
Politico· 18 hours agoS. doses this upcoming season, according to Ayanna Santos, head of the RSV franchise in Sanofi’s U.S. vaccines unit. The CDC is working ...
Texas cities and counties are destroying expired Narcan. Some say it could still be used to save...
KRGV Rio Grande Valley· 2 days agoSign up for The Brief, The Texas Tribune’s daily newsletter that keeps readers up to speed on the...
Acasti Pharma to Attend BIO International Convention 2024
Digital Journal· 1 day agoAcasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical ...
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible...
Benzinga· 3 days agoThe U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational ...